Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitors

Abstract

The use of anticancer drugs targeting specific molecular tumor characteristics is rapidly increasing in clinical practice, but selecting patients to benefit from these remains a challenge. It has been suggested that organoid cultures would be ideally suited to test drug responses in vitro. Here we describe and characterize in depth a case of ETV6-NTRK3 gene fusion-positive secretory carcinoma of the salivary glands and corresponding organoid cultures that responded and subsequently acquired resistance to TRK targeting therapy with larotrectinib. This case-culture-characterization illustrates the advances made in precision oncology, but also exposes important caveats in using organoids to predict treatment response.

Keywords: NTRK3 receptor [Mesh]; Organoids [Mesh]; Precision medicine [Mesh]; Salivary gland neoplasms [Mesh].